厄贝沙坦对扩张型心肌病患者氧化应激及炎症的影响  

Effects of irbesartan on oxidative stress and inflammation in patients with dilated cardiomyopathy

作　　者：王俊峰[1] 何圆圆[2] 党书毅[1] 周明[1] 段班燕[1] 

机构地区：[1]湖北医药学院附属十堰市太和医院心内科,湖北十堰442000 [2]湖北医药学院附属十堰市太和医院血液科,湖北十堰442000

出　　处：《实用药物与临床》2013年第11期1011-1014,共4页Practical Pharmacy and Clinical Remedies

摘　　要：目的观察厄贝沙坦对扩张型心肌病患者心室重构的影响。方法将96例扩张型心肌病患者随机分为厄贝沙坦组(54例)与对照组(42例),两组均予常规治疗,厄贝沙坦组加用厄贝沙坦,疗程2个月,并随访至半年。检测两组治疗前后氧化应激、炎症、超声的改变以及半年内的不良心血管事件。结果治疗后两组氧化应激、炎症均较治疗前显著降低,左室功能指标好转(P<0.05),而厄贝沙坦组尤为明显(P<0.05)。与对照组比较,厄贝沙坦组的半年心血管不良事件发生率更低(P<0.05)。结论厄贝沙坦可降低氧化应激、炎症,改善左室功能,减少心血管不良事件的发生。Objective To investigate the effects of irbesartan on oxidative stress and inflammation in patients with dilated cardiomyopathy （ DCM ）. Methods 96 patients with DCM were randomly divided into the irbesartan group （ n = 54） and the control group （ n = 42 ）. Each group was given traditional treatment while the irbesartml group was additionally treated with irbesartan for 2 months. The oxidative stress,inflammatory markers and echocardiography were detected in both groups before and after treatment. All patients were followed up for 6 months. Results After treatment, the oxidative stress, serum level of inflammatory cytokines and left ventricular function were improved （ P 〈 0. 05 ）, especially in the irbesartan group （ P 〈 0. 05 ）. Compared to the control group, lower cardiovascular adverse e- vents were occurred in the irbesartan group （ P 〈 0. 05 ）. Conclusion Irbesartan can lower oxidative stress and serum level of inflammatory cytokine, improve left ventricular function and reduce adverse cardiovascular events in patients with DCM.

关 键 词：厄贝沙坦 扩张型心肌病 氧化应激 炎症 

分 类 号：R542.2[医药卫生—心血管疾病]